MedTrace Logo

SP2086 Pharmacokinetic Study in Renal Insufficiency Patients

NCT02815774 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-06-28

No results posted yet for this study

Summary

The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.

Conditions

  • Renal Insufficiency

Interventions

DRUG

SP2086

all subjects were given SP2086 50mg only one time.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jia Miao, P.H.D · West China Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02815774 on ClinicalTrials.gov